BioCryst wins ap­proval for HAE pill and charges half-a-mil­lion dol­lars, but will any­one take it?

Six years af­ter the FDA OK’d their flu an­tivi­ral peramivir, BioCryst has notched an­oth­er ap­proval.

The North Car­oli­na-based biotech an­nounced Thurs­day that the FDA had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER